AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
June 10 2024 - 8:55AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), today announced that
Thomas K. Equels, MS JD, Chief Executive Officer of AIM will
participate in the Virtual Investor Pitch Conference on Monday,
June 17, 2024 at 1:00 PM ET.
As part of the event, Mr. Equels will provide an
“elevator pitch” and outline the Company’s upcoming milestones.
Additionally, investors and interested parties will have the
opportunity to submit questions live during the event.
Participating companies will answer as many questions as possible
in the time allowed.
A live video webcast of the presentation will be
available on the Events page of the Company’s website
(aimimmuno.com). A webcast replay will be available two hours
following the live presentation and will be accessible for 90
days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Jul 2024 to Aug 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Aug 2023 to Aug 2024